November 19, 2020 — MIM Software Inc. announced a collaboration with Peter MacCallum Cancer Centre (Peter Mac) in support of its Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) program.
Peter Mac and MIM Software will collaborate to improve prostate cancer patient management through the program. ProsTIC will develop tools that aid clinicians in oncologic cancer staging, treatment planning, therapy response assessment, and recurrence detection.
Peter Mac introduced the ProsTIC program to expand clinical trial research, establish an educational hub on the benefits of new technology, and conduct further research on next-generation targets.
"The Prostate Cancer Theranostics and Imaging Centre of Excellence at Peter MacCallum Cancer Centre in Melbourne is proud to collaborate with MIM Software to enhance our program," said Professor Michael Hofman, Nuclear Medicine physician, and physician-scientist at Peter Mac. "Clinical researchers will collaborate with MIM Software to perform advanced analysis of PET images and develop new methods for whole-body tumor analysis. We hope to identify new prognostic or predictive imaging biomarkers and also contribute to the development of artificial intelligence algorithms that will improve patient outcomes through improved, personalized medicine."
PET/CT imaging is an essential tool for disease identification. However, the process of differentiating a tumor from normal uptake on oncologic PET/CT scans is time-consuming. There is also an immense amount of quantitative data in these exams not currently captured and potentially important for determining a patient's prognosis. The collection of this data will result in more personalized patient care, including treatment response assessment.
"There is a demand for more quantitation to increase clinician confidence, and MIM Software can play a significant role in helping to predict patient outcomes as a result of data-driven decision-making," said Aaron Nelson, M.D., Chief Medical Officer of MIM Software Inc. "This collaboration with Peter MacCallum Cancer Centre will help develop a reproducible and efficient method for quantification of FDG and Ga-68 PSMA PET lesions."
For more information: www.mimsoftware.com
March 12, 2026 
